60th ASH Annual Meeting
Training Activities Material Interest Disclosures

FRIDAY

Training Program Directors’ Workshop
Special-Interest Session

Friday 11:00 a.m. – 2:00 p.m. The Auditorium, Petco Park

Chair:
HETTY E. CARRAWAY, MD, MBA, Cleveland Clinic, Cleveland, OH

Speakers:
ELAINE A. MUCHMORE, MD , University, San Diego, CA
LAURA EDGAR, EDD, CAE, ACGME, Chicago, IL

Program Director Role in Clinical Competency Committee Evaluation
MICHAEL LINENBERGER, MD, Seattle Cancer Care Alliance, Seattle, WA

Resiliency in Fellowship
ALICE MA, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC
ANN S. LACASCE, MD, MSC, Dana-Farber Cancer Institute, Boston, MA
ANNIE IM, MD, University of Pittsburgh Cancer Institute, Pittsburgh, PA

Top Ten Pearls and Pitfalls for Fellowship Program Directors

This workshop offers an interactive forum for fellowship directors to learn about issues facing them and engage in topic-based conversations with educators, regulators, and other training program directors. The workshop is designed to facilitate discussion and the sharing of best practices in critical training areas.

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

ASH designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:
CARRAWAY: Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Agios: Consultancy, Speakers Bureau; Novartis: Speakers Bureau; FibroGen: Consultancy; Balaxa: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ACGME: Membership on an entity's Board of Directors or advisory committees; Jazz: Speakers Bureau.

MUCHMORE: ACGME: Membership on an entity's Board of Directors or advisory committees.

EDGAR: Nothing to disclose.

LINENBERGER: ABIM Hematology Board Exam Committee: Membership on an entity's Board of Directors or advisory committees; American Society of Clinical Oncology: Membership on an entity's Board of Directors or advisory committees; American Society for Apheresis: Membership on an entity's Board of Directors or advisory committees.

MA: CSL Behring: Membership on an entity's Board of Directors or advisory committees; CVS Caremark/Accordant: Consultancy; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; Shire: Consultancy.

LACASCE: Research to Practice: Speakers Bureau; Seattle Genetics: Consultancy, Honoraria; Bristol-Myers Squibb: Other: Data safety and monitoring board; Humanigen: Consultancy, Honoraria.

IM: Nothing to disclose.
ASH-a-Palooza

Moderator:
TED WUN, UC Davis Comprehensive Cancer Center, Sacramento, CA

The "Trainee Day" attendees may know from past annual meetings has been re-imagined as ASH-a-Palooza! What has emerged is a new educational experience that will offer a relaxed, open learning environment for trainees in a festival-like setting with multiple opportunities for micro learning.

ASH-a-Palooza will be held the Friday before the start of the official annual meeting at Petco Park, home of the San Diego Padres professional baseball team. The stadium is across the street from the convention center and is adjacent to the Omni San Diego Hotel.

There is no fee to attend, and registration is not required; however, attendance will be limited and access to the event will be on a first-come, first-served basis.

Disclosures:
WUN: Nothing to disclose.

Hem 411 Info Booths

<table>
<thead>
<tr>
<th>Friday</th>
<th>12:00 p.m. – 5:00 p.m.</th>
<th>Left Field Concourse</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Petco Park</td>
<td></td>
</tr>
</tbody>
</table>

Speakers:

Hem 411 Info Booth: Blood Journals
WENDY STOCK, MD, University of Chicago, Chicago, IL
JULIE PANEPINTO, MD, MSPH, The Medical College of WI, Milwaukee, WI
ROBERT S. NEGRIN, MD, Stanford University, Stanford, CA
MARGARET GOODELL, PhD, Center for Cell and Gene Therapy, Houston, TX
NANCY BERLINER, MD, Brigham and Women's Hospital, Boston, MA

Hem 411 Info Booth: Sickle Cell Disease

Hem 411 Info Booth: Diversity

Hem 411 Info Booth: Awards

Hem 411 Info Booth: PhD

Hem 411 Info Booth: Advocacy

Hem 411 Info Booth: National Institute of Health (NIH)

Hem 411 Info Booth: AYA
LEIDY ISENALUMHE, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
ALEXANDER A BOUCHER, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Hem 411 Info Booth: Wellness

Hem 411 Info Booth: Quality

Bone Marrow Biopsy - Interactive Demo - Table 1
ALFRED IAN LEE, MD, PhD, Yale University School of Medicine, New Haven, CT

Bone Marrow Biopsy - Interactive Demo - Table 2
HANNY AL-SAMKARI, MD, Massachusetts General Hospital, Dana-Farber Cancer Institute, Harvard University, Boston, MA

Disclosures:
STOCK: Amgen: Consultancy; Amgen: Honoraria; Jazz: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Varifarma: Honoraria.

PANEPINTO: National Institute of Arthritis and Musculoskeletal and Skin Diseases: Research Funding; Health Resources and Services Administration: Research Funding.

NEGRI: Nothing to disclose.

GOODELL: Nothing to disclose.

BERLINER: Nothing to disclose.

ISENALUMHE: Nothing to disclose.

BOUCHER: Nothing to disclose.

LEE: Nothing to disclose.

AL-SAMKARI: Agios: Consultancy.

ASH-a-Palooza Kickoff Talk

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday 12:45 p.m. – 1:00 p.m.</td>
<td>Section 108 Petco Park</td>
<td></td>
</tr>
</tbody>
</table>

ASH Talks

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday 1:00 p.m. – 5:00 p.m.</td>
<td>Section 108 Petco Park</td>
<td></td>
</tr>
</tbody>
</table>

Each ASH Talk session will be an 18- to 20-minute presentation, similar to a TED Talk, with no podium and minimal slides.

Speakers:

Why Hematology? Here's Why
RAYNE ROUCE, MD, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX

Show ME the Money – Negotiating Your First Job
JOSEPH MIKHAEL, MD, FRCPC, MED, Mayo Clinic Arizona, Scottsdale, AZ

Driving CARs – Where Are We Going?
SAAR I. GILL, MD, PhD, University of Pennsylvania, Philadelphia, PA

A Cool PhD Story
ELLI PAPAEMMANUIL, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Self-Care in Health Care: Surviving and Thriving
TAIT D. SHANAFELT, MD, Stanford University, Stanford, CA

Disclosures:
ROUCE: Nothing to disclose.
MIKHAEL: Onyx, Celgene, Sanofi, AbbVie: Research Funding.
GILL: Novartis: Research Funding; Carisma Therapeutics: Equity Ownership; Estelisa: Consultancy, Membership on an entity's Board of Directors or advisory committees.
PAPAEMMANUIL: Nothing to disclose.
SHANAFELT: Mayo Clinic: Patents & Royalties: Physician Well-being Index, Medical Student Well-being Index, Well-being index; Abbvie: Research Funding; GlaxoSmithKline: Research Funding; Celgene: Research Funding; Janssen: Research Funding; Genentech: Research Funding; Pharmacyclics: Research Funding.

Blood Drops: Hematology 101: An entry level clinical topic

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday 1:30 p.m. – 4:45 p.m.</td>
<td>Western Metal Concourse Petco Park</td>
<td></td>
</tr>
</tbody>
</table>

Speakers:

How Do You Use the 4Ts score and PF4/heparin ELISA to screen for HIT
ADAM CUKER, MD, MS, University of Pennsylvania, Philadelphia, PA
When should ITP Patient Be Hospitalized?
ELISABETH BATTINELLI, MD, PhD, Brigham and Women’s Hospital, Boston, MA

Drugs that Cause Thrombocytopenia – What Is Your Mnemonic?
RYAN ZARYCHANSKI, MD, MSC, FRCPC, Cancercare Manitoba University of Manitoba, Winnipeg, MB, Canada

Iron Deficiency in Pregnancy
MICHELLE SHOLZBERG, MD, St. Michael's Hospital, Toronto, Canada

Disclosures:
CUKER: Spark Therapeutics: Research Funding; Synergy: Consultancy; Genzyme: Consultancy; Kedrion: Membership on an entity's Board of Directors or advisory committees.
BATTINELLI: Sanofi: Consultancy.
ZARYCHANSKI: Nothing to disclose.
SHOLZBERG: Octapharma: Research Funding; Shire: Research Funding; CSL Behring: Research Funding; Amgen: Research Funding.

Blood Drops: Hematology 301: A higher-level clinical topic

Friday 1:30 p.m. – 4:45 p.m.  Western Metal Concourse
Petco Park

Speakers:
The Clock is Ticking: managing acute leukemia in the first 24 hrs
JESSICA K. ALTMAN, MD, Northwestern Univ., Chicago, IL

Clinical Applications for Next Generation Sequencing
COURTNEY D. DINARDO, MD, MSC, UT MD Anderson Cancer Center, Houston, TX

Practical Hempath/Know your Cluster Designations
DEBORAH ORNSTEIN, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Scientific Communication: Explaining Your Science to a Lay Audience
MARGARET V. RAGNI, MD, MPH, University of Pittsburgh, Pittsburgh, PA

Disclosures:
ALTMAN: FujiFilm: Other: payment to the institution to conduct clinical trial work; Genetech: Other: Payment to the institution to conduct clinical trial work; Novartis: Membership on an entity's Board of Directors or advisory committees; Epizyme: Other: payment to the institution to conduct clinical trial work; Immune Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Agios: Membership on an entity's Board of Directors or advisory committees, Other: payment to the institution to conduct clinical trial work; Bayer: Other: Payment to the institution to conduct clinical trial; Inmune: Other: payment to the institution to conduct clinical trial work; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: payment to the institution to conduct clinical trial work; Boehringer Ingelheim: Other: payment to the institution to conduct clinical trial work; GSK: Other: payment to the institution to conduct clinical trial work; BMS: Membership on an entity's Board of Directors or advisory committees; Amgen: Other: Payment to the institution to conduct clinical trial work; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Celator: Other: payment to the institution to conduct clinical trial work; Cyclacel: Other: payment to the institution to conduct clinical trial work.

DINARDO: Agios: Consultancy; Medimmune: Honoraria; Abbvie: Honoraria; Bayer: Honoraria; Celgene: Honoraria; Karyopharm: Honoraria.

ORNSTEIN: Nothing to disclose.

RAGNI: SPARK: Consultancy, Research Funding; Shire: Research Funding; Novo Nordisk: Research Funding; Biogen: Membership on an entity's Board of Directors or advisory committees, Research Funding; CSL Behring: Research Funding; Abylan: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bioverativ: Consultancy, Research Funding; Sangamo: Research Funding; MOGAM: Membership on an entity's Board of Directors or advisory committees.

Blood Drops: Sickle Cell Disease: Topics related to SCD

Friday 1:30 p.m. – 4:45 p.m.  Western Metal Concourse
Petco Park

Speakers:
Preventing Long Term complications in SCD
E. Leila Clay, MD, Johns Hopkins University, St. Petersburg, FL

Key Issues: Health Maintenance in SCD
Sophie Lanzkron, MD, Johns Hopkins Medicine, Baltimore, MD

Michelle P. Zeller, MD, McMaster University, Hamilton, ON, Canada

Pros and Cons of being a Clinician Educator doing Research in SCD
Adetola A. Kassim, MD, MS, Vanderbilt University Medical Center, Nashville, TN

Disclosures:
Clay: Nothing to disclose.
Lanzkron: NHLBI: Research Funding; PCORI: Research Funding; GBT: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Prolong: Research Funding; Selexys: Research Funding; Ironwood: Research Funding.
Zeller: Canadian Blood Services: Employment; Pfizer: Membership on an entity's Board of Directors or advisory committees.
Kassim: Nothing to disclose.

Blood Drops: Hematology 201: A mid-level clinical topic

Friday 1:30 p.m. – 4:45 p.m. Western Metal Concourse
Petco Park

Speakers:

Approach to Inherited Thrombocytopenia
Amy E. Geddis, MD, PhD, Seattle Children's Hospital, Seattle, WA

What to Do When Pre-op Patient has Abnormal PT or PTT
Rebecca Kruse-Jarres, Bloodworks Northwest, Seattle, WA

DLBCL Genomics
Christopher R. Flowers, MD, MS, Winship Cancer Institute of Emory University, Atlanta, GA

Identifying White Cell Disorder on the Peripheral Smear
Anne T. Neff, MD, Cleveland Clinic, Cleveland, OH

Disclosures:
Geddis: Nothing to disclose.
Kruse-Jarres: Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Grifols: Membership on an entity's Board of Directors or advisory committees; CSL Behring: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novo Nordisk: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche/Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Flowers: Pharmacyclics: Research Funding; Millennium/Takeda: Research Funding; Janssen Pharmaceutical: Research Funding; Genentech/Roche: Research Funding; Gilead: Research Funding; Celgene: Research Funding; Beigene: Consultancy; Acerta: Consultancy; Abbvie: Research Funding; Pharmacyclics/Janssen: Consultancy; Karyopharm: Consultancy; Gilead: Consultancy; Genentech/Roche (unpaid): Consultancy; Denovo Biopharma: Consultancy; Bayer: Consultancy; Abbvie: Consultancy; TG Therapeutics: Research Funding.

Neff: ABIM: Other: Hematology Exam Committee; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; Shire: Membership on an entity's Board of Directors or advisory committees.

Blood Drops: Adolescent Young Adult Topics and Blood Advances Editor

Friday 1:30 p.m. – 4:45 p.m. Western Metal Concourse
Petco Park

Speakers:

Transitions from Peds Perspective
Tara O. Henderson, MD, MPH, Tufts Medical Center, Chicago, IL

Transitions from Adult Perspective
Wendy Stock, MD, University of Chicago, Chicago, IL
The Birds and the Bees: Fertility Preservation
ALISON W. LOREN, MD, MS, Perelman Center For Advanced Medicine, Philadelphia, PA

Blood Advances Editor: Volunteering Your Skills Overseas
ROBERT S. NEGRIN, MD, Stanford University, Stanford, CA

Disclosures:
HENDERSON: Seattle Genetics: Research Funding.
STOCK: Amgen: Consultancy; Amgen: Honoraria; Jazz: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Varifarma: Honoraria.
LOREN: Nothing to disclose.
NEGRIN: Nothing to disclose.

Blood Drops: Wellness: Topics to help your well-being
Friday 1:30 p.m. – 4:45 p.m. Western Metal Concourse Petco Park

Speakers:
Survival Tips for When It Seems Like You’re a Cog in a Broken Machine
DAVID P. STEENSMA, MD, Dana-Farber Cancer Institute, Boston, MA

Mean Docs? Harassment and Bullying
SCOTT MOERDLER, MD, Rutgers Cancer Institute of New Jersey, New Brunswick

Medicine and parenthood: Surviving and thriving during the early years
LISA K. HICKS, MD, MSC, St. Michael's Hospital, Toronto, ON, Canada

Telling It Like It Is - Essays About Medicine
MIKKAEL A. SEKERES, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Disclosures:
STEENSMA: Nothing to disclose.
MOERDLER: Nothing to disclose.
HICKS: Nothing to disclose.
SEKERES: Nothing to disclose.

Blood Drops: Career 101: Early career planning topics
Friday 1:30 p.m. – 4:45 p.m. Western Metal Concourse Petco Park

Speakers:
So You Want to Be a Benign Hematologist
RAKHI P. NAIR, MD, Johns Hopkins Hospital, Baltimore, MD

#HowITweet
NAVEEN PEMMARAJU, MD, The University of Texas MD Anderson Cancer Center, Bellaire, TX

Knocking your fellowship interview out of the park! Tips to make sure your interview day is a #homerun
HEETY E. CARRAWAY, MD, MBA, Cleveland Clinic, Cleveland, OH

Academic Career Development in Pediatric Hematology
NEIL A GOLDENBERG, MD, PhD, All Children's Hospital Johns Hopkins Medicine, St Petersburg, FL

Disclosures:
PEMMARAJU: novartis: Research Funding; amana: Research Funding; SagerStrong Foundation: Research Funding; abbr: Research Funding; plexikon: Research Funding; Affimetrics: Research Funding; collectis: Research Funding; stemline: Consultancy, Honoraria, Research Funding; celgene: Consultancy, Honoraria; daischi sankyo: Research Funding.
CARRAWAY: Amgen: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Speakers Bureau; Agios: Consultancy, Speakers Bureau; Balaxa: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Balaxa: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; FibroGen: Consultancy; FibroGen: Consultancy; Jazz: Speakers Bureau; Novartis: Speakers Bureau; Jazz: Speakers Bureau; Novartis: Speakers Bureau.

GOLDENBERG: Nothing to disclose.

**Blood Drops: Career 201: Mid-career topics, the end of fellowship is in sight**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday</td>
<td>1:30 p.m. – 4:45 p.m.</td>
<td>Western Metal Concourse</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Petco Park</td>
</tr>
</tbody>
</table>

**Speakers:**

How to Say No  
ALICE MA, MD, University of North Carolina At Chapel Hill, Chapel Hill, NC

How Do I Stay Current with Literature  
JASON R. GOTLIB, MD, MS, Stanford Cancer Center, Stanford, CA

Crafting Your Elevator Pitch  
JENNIFER C. KESSELHEIM, MD, MED, Dana-Farber Cancer Institute, Boston, MA

Transitioning from Academia to Industry  
BENJAMIN KIM, MD, MPHIL, BioMarin Pharmaceutical Inc., Novato, CA

**Disclosures:**

**MA:** CSL Behring: Membership on an entity's Board of Directors or advisory committees; CVS Caremark/Accordant: Consultancy; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; Shire: Consultancy.

**GOTLIB:** Novartis: Consultancy, Honoraria, Research Funding; Blueprint Medicines: Consultancy, Honoraria, Research Funding; Deciphera: Consultancy, Honoraria, Research Funding; Incyte: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Promedior: Research Funding; Kartos: Consultancy.

**KESSELHEIM:** Nothing to disclose.

**KIM:** BioMarin Pharmaceutical Inc.: Employment, Equity Ownership.

**Blood Drops: Career 301: Career options**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday</td>
<td>1:30 p.m. – 4:45 p.m.</td>
<td>Western Metal Concourse</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Petco Park</td>
</tr>
</tbody>
</table>

**Speakers:**

Extra Degrees… of Freedom?  
MARC J KAHN, MD, MBA, Tulane University, New Orleans, LA

Practice Made Perfect: The Secret to Success in Private Practice  
GWENDOLYN HO, MD, MAS, The Permanente Medical Group, Kaiser, Sacramento, CA

Funding Opps at the PhD and PostDoc Level  
ALISA S. WOLBERG, PhD, University of North Carolina, Chapel Hill, NC

Must See CV  
TED WUN, UC Davis Comprehensive Cancer Center, Sacramento, CA

**Disclosures:**

**KAHN:** Association of American Medical Colleges: Membership on an entity's Board of Directors or advisory committees; National Residency Match Program: Membership on an entity's Board of Directors or advisory committees; National Residency Matching Program: Membership on an entity's Board of Directors or advisory committees; Association of American Medical Colleges: Membership on an entity's Board of Directors or advisory committees; National Residency Match Program: Membership on an entity's Board of Directors or advisory committees; National Residency Matching Program: Membership on an entity's Board of Directors or advisory committees.

**HO:** Nothing to disclose.
WOLBERG: Novo Nordisk: Research Funding; GlaxoSmithKline: Employment.
WUNT: Janssen: Membership on an entity's Board of Directors or advisory committees; Glycomimetics, Inc.: Research Funding; Emmaus, Inc.: Membership on an entity's Board of Directors or advisory committees.

Blood Drops: PhD: Topics relevant to researchers

Friday 1:30 p.m. – 4:45 p.m. Western Metal Concourse
Petco Park

Speakers:

Leading a Translational Research Team
MARIE BLEAKLEY, MBBS, PhD, MMSC, Fred Hutchinson Cancer Resch. Ctr., Seattle, WA

Navigating the Hematology Field as a Basic Scientist
GRANT CHALLEN, PhD, Washington University School of Medicine, St Louis, MO

Opportunities for Scientists in Hematology: Nothing Basic About Discovery
DANIEL E. BAUER, MD, PhD, Boston Children's Hospital / Dana-Farber Cancer Institute, Cambridge, MA

PhDs Can Love Hematology
MICHAEL G. KHARAS, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Disclosures:
BLEAKLEY: Nothing to disclose.
CHALLEN: Nothing to disclose.
BAUER: Nothing to disclose.
KHARAS: Nothing to disclose.

Blood Buddies/Mentor Session 1

Friday 2:30 p.m. – 3:00 p.m. Section 124 -The Porch
Petco Park

Speakers:

Adult Clinical Non-Malignant Hem
LISA BAUMANN KREUZIGER, MD, MS, BloodCenter of Wisconsin, Menomonee Falls, WI
ARELIA L. MARSHALL, MD, Mayo Clinic, Rochester, MN
MICHAEL LINENBERGER, MD, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
NATHAN T. CONNELL, MD, MPH, Brigham and Women's Hospital, Boston, MA
CHANCELLOR E. DONALD, MD, Tulane University School of Medicine, New Orleans, LA
KEITH R. MCCRAE, MD, Cleveland Clinic, Cleveland, OH
DAVID A. GARCIA, University of Washington, Seattle, WA
LESLIE SKEITH, MD, University of Calgary, Calgary, AB, Canada

Pediatric Clinical Non-Malignant Hem
JENNY M. DESPOTOVIC, DO, MS, Texas Children's Hospital/Baylor College of Medicine, Houston, TX
DEEPA MANWANI, MD, Children's Hospital at Montefiore, Bronx, NY
CINDY NEUNERT, MD, Columbia University, New York, NY
AMY E. GEDDIS, MD, PHD, Seattle Children's Hospital, Seattle, WA
SARAH H. O'BRIEN, MD, MSC, Nationwide Children's Hospital, Columbus, OH

BMT Peds and Adult
MARK R. LITZOW, MD, Mayo Clinic, Rochester, MN
JOHN F. TISDALE, MD, National Institutes of Health, Bethesda, MD
ALEX F. HERRERA, MD, City of Hope, Duarte, CA
SAAD Z. USMANI, MD, Levine Cancer Institute, Charlotte, NC
LINDA J. BURNS, MD, National Marrow Donor Program/Be the Match, Minneapolis, MN
ANGELA R. SMITH, MD, MS, University of Minnesota, Minneapolis, MN
Laboratory & Translational Hem

JEFFREY W. TYNER, PhD, Oregon Health & Science University, Portland, OR
KARIN M. HOFFMEISTER, MD, Blood Research Center Institute, Blood Center of Wisconsin, Milwaukee, WI
KATHRYN G. ROBERTS, PhD, St. Jude Children's Research Hospital, Memphis, TN
LISA M. RIMSZA, MD, Mayo Clinic - Scottsdale, Scottsdale, AZ
KEITH R. MCCRAE, MD, Cleveland Clinic, Cleveland, OH
ROBERT A. BRODSKY, MD, Johns Hopkins University, Baltimore, MD
ANN MULLALLY, MD, Brigham and Women's Hospital, Boston, MA
DAVID M WEINSTOCK, MD, Dana Farber Cancer Institute, Boston, MA

PhD Careers

LAWRENCE H. BOISE, PhD, Emory University, Atlanta, GA
MOHANDAS NARLA, DSc, New York Blood Center, New York
BELINDA RENE AVALOS, MD, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC

Adult Clinical Malignant Hem

JONATHON B. COHEN, MD, MS, Emory University, Atlanta, GA
AMY E. DEZERN, MD, Johns Hopkins University, Baltimore, MD
LORETTA J. NASTOUPIL, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
DANIEL A POLLYEA, MD, University of Colorado, Denver, CO
JENNIFER R. BROWN, MD, PHD, Dana-Farber Cancer Institute, Newton, MA
AZIZ NAZHA, Cleveland Clinic, Cleveland, OH
ALISON J. MOSKOWITZ, MD, Memorial Sloan Kettering Cancer Center, New York, NY
LESLIE RENEE ELLIS, MD, MSHPEd, Wake Forest University School of Medicine, Winston Salem, NC
NITIN JAIN, MD, MD Anderson Cancer Center, Houston, TX
PHILLIP SCHEINBERG, MD, Division of Hematology, Hospital A Beneficência Portuguesa, Sao Paulo, Brazil
LINDSAY A.M. REIN, MD, Duke University School of Medicine, Durham, NC

Pediatric Clinical Malignant Hem

INGA HOFMANN, MD, University of Wisconsin, Madison, WI
MIGNON L. LOH, MD, University of California Benioff Children's Hospital, San Francisco, CA
SARAH K. TASIAN, MD, Children's Hospital of Philadelphia, Philadelphia, PA

Disclosures:

BAUMANN KREIZIGER: Nothing to disclose.
MARSHALL: Nothing to disclose.
LINENBERGER: American Society of Clinical Oncology: Membership on an entity's Board of Directors or advisory committees; American Society for Apheresis: Membership on an entity's Board of Directors or advisory committees; ABIM Hematology Board Exam Committee: Membership on an entity's Board of Directors or advisory committees.
CONNELL: The Michael H. Flanagan Foundation: Membership on an entity's Board of Directors or advisory committees.
DONALD: Nothing to disclose.
MCRAE: Nothing to disclose.
GARCIA: Genzyme Corporation: Consultancy; Portola: Research Funding; Shingoi: Consultancy; Bristol Meyers Squibb: Consultancy; Daiichi Sankyo: Research Funding; Retham Technologies LLC: Consultancy; Incyre: Research Funding; Jansen: Consultancy, Research Funding; Pfizer: Consultancy; Boehringer Ingelheim: Consultancy; Alexion: Consultancy.
SKEITH: CSL Behring: Research Funding; Leo Pharma: Honoraria.
DISPOTOVIC: Sanofi: Consultancy; Amgen: Research Funding; Novartis: Research Funding.
MANWANE: Nothing to disclose.
NEUBERT: Sanofi-Genzyme: Consultancy; Genzyme: Membership on an entity's Board of Directors or advisory committees.
GEDDIS: Nothing to disclose.
O'BRIEN: Nothing to disclose.
LITZOW: Nothing to disclose.
TISDALE: Nothing to disclose.
HERRERA: Bristol-Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Merck, Inc.: Consultancy, Research Funding; Pharmacycels: Consultancy, Research Funding; Pharmacycels: Consultancy, Research Funding; AstraZeneca: Research Funding; Merck, Inc.: Consultancy, Research Funding; Gilead Sciences: Research Funding; Gilead Sciences: Research Funding; KITE Pharma: Consultancy, Research Funding; Immune Design: Research Funding; KITE Pharma: Consultancy, Research Funding; Seattle Genetics: Research Funding; AstraZeneca: Research Funding; Genentech: Consultancy, Research Funding; Immune Design: Research Funding.
AVALOS: Consultancy, Research Funding; Gilead: Board of Directors or advisory committees; Agios: committees, Research Funding;

MULLALLY: Pharmacyclics, Sanofi, Seattle Genetics, Takeda: Research Funding;

NASTOUPIL: Research Funding;

BOISE: AstraZeneca: Honoraria; Abbvie: Consultancy.

NARLA: Nothing to disclose.

AVALOS: Juno: Membership on an entity’s Board of Directors or advisory committees.

COHEN: AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Bristol-Myers Squibb: Research Funding; Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Infinity Pharmaceuticals: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Bristol-Myers Squibb: Research Funding; Infinity Pharmaceuticals: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Janssen: Research Funding; Millennium: Consultancy, Membership on an entity’s Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Research Funding; Pharmacyclics: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Millennium: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Takeda: Research Funding; BioInvent: Consultancy; Seattle Genetics: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Research Funding; Genentech/Roche, Monsanto: Consultancy; AstraZeneca, JAX, Samumed, Regeneron, Sun Pharma, Priscien: Patents & Royalties.

SMITH: Nothing to disclose.

RIMSZA: NanoString: Other: Inventor on the patent for the Lymph2Cx assay.

McCRAE: Nothing to disclose.

ROBERTS: Therapeutics: Research Funding;

WEINSTOCK: Traversa: Equity Ownership; Novartis, Dragonfly, Traversa, DiTerity, Traversa: Consultancy; Novartis, Astra Zeneca, Abbvie, Aileron, Surface Oncology, Daiichi Sankyo: Research Funding; Novartis: Consultancy, Research Funding; Genentech/Roche, Monsanto: Consultancy; Astra Zeneca, JAX, Samumed, Regeneron, Sun Pharma, Priscien: Patents & Royalties.

SMITH: Nothing to disclose.

RIMSZA: NanoString: Other: Inventor on the patent for the Lymph2Cx assay.

McCRAE: Nothing to disclose.

ROBERTS: Therapeutics: Research Funding;

WEINSTOCK: Traversa: Equity Ownership; Novartis, Dragonfly, Traversa, DiTerity, Traversa: Consultancy; Novartis, Astra Zeneca, Abbvie, Aileron, Surface Oncology, Daiichi Sankyo: Research Funding; Novartis: Consultancy, Research Funding; Genentech/Roche, Monsanto: Consultancy; Astra Zeneca, JAX, Samumed, Regeneron, Sun Pharma, Priscien: Patents & Royalties.

NARLA: Nothing to disclose.

AVALOS: Juno: Membership on an entity’s Board of Directors or advisory committees.

COHEN: AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Bristol-Myers Squibb: Research Funding; Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Infinity Pharmaceuticals: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Bristol-Myers Squibb: Research Funding; Infinity Pharmaceuticals: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Janssen: Research Funding; Millennium: Consultancy, Membership on an entity’s Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Research Funding; Pharmacyclics: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Millennium: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Takeda: Research Funding; BioInvent: Consultancy; Seattle Genetics: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Research Funding; Genentech/Roche, Monsanto: Consultancy; Astra Zeneca, JAX, Samumed, Regeneron, Sun Pharma, Priscien: Patents & Royalties.

SMITH: Nothing to disclose.

RIMSZA: NanoString: Other: Inventor on the patent for the Lymph2Cx assay.

McCRAE: Nothing to disclose.

ROBERTS: Therapeutics: Research Funding;

WEINSTOCK: Traversa: Equity Ownership; Novartis, Dragonfly, Traversa, DiTerity, Traversa: Consultancy; Novartis, Astra Zeneca, Abbvie, Aileron, Surface Oncology, Daiichi Sankyo: Research Funding; Novartis: Consultancy, Research Funding; Genentech/Roche, Monsanto: Consultancy; Astra Zeneca, JAX, Samumed, Regeneron, Sun Pharma, Priscien: Patents & Royalties.

NARLA: Nothing to disclose.
on an entity's Board of Directors or advisory committees; **Servier**: Research Funding; **Verastem**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Novartis**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Verastem**: Research Funding; **ADC Therapeutics**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Cellectis**: Research Funding; **Pfizer**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Adaptive Biotechnologies**: Research Funding; **Servier**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Novimmune**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Pharmacyclics**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **AbbVie**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Janssen**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **AstraZeneca**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Novartis**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Verastem**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **ADC Therapeutics**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Pfizer**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Adaptive Biotechnologies**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Novimmune**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Pharmacyclics**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **AbbVie**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Janssen**: Honoraria, Membership on an entity's Board of Directors or advisory committees.

**Scheinberg**: Novartis: Consultancy, Speakers Bureau; Pfizer: Speakers Bureau; Janssen: Honoraria, Research Funding.

**Rein**: Nothing to disclose.

**Hofmann**: Nothing to disclose.

**LoH**: Nothing to disclose.

**Tasian**: Nothing to disclose.

### Blood Buddies/Mentor Session 2

**Friday** 3:30 p.m. – 4:00 p.m.  **Section 124 - The Porch**  
**Petco Park**

**Speakers:**

**PhD Careers**

**Lawrence H. Boise**, PhD, Emory University, Atlanta, GA  
**Mohandas Narla**, DSc, New York Blood Center, New York  
**Belinda Rene Avalos**, MD, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC

**BMT Peds and Adult**

**Mark R. Litzow**, MD, Mayo Clinic, Rochester, MN  
**John F. Tisdale**, MD, National Institutes of Health, Bethesda, MD  
**Alex F. Herrera**, MD, City of Hope, Duarte, CA  
**Saad Z. Usmani**, MD, Levine Cancer Institute, Charlotte, NC  
**Linda J. Burns**, MD, National Marrow Donor Program/Be the Match, Minneapolis, MN  
**Angela R. Smith**, MD, MS, University of Minnesota, Minneapolis, MN

**Laboratory & Translational Hem**

**Jeffrey W. Tyner**, PhD, Oregon Health & Science University, Portland, OR  
**Karin M. Hoffmeister**, MD, Blood Research Center Institute, Blood Center of Wisconsin, Milwaukee, WI  
**Kathryn G. Roberts**, PhD, St. Jude Children's Research Hospital, Memphis, TN  
**Lisa M. Rimsza**, MD, Mayo Clinic - Scottsdale, Scottsdale, AZ  
**Keith R. McCrae**, MD, Cleveland Clinic, Cleveland, OH  
**Robert A. Brodsky**, MD, Johns Hopkins University, Baltimore, MD  
**Ann Mullally**, MD, Brigham and Women's Hospital, Boston, MA  
**David M Weinstock**, MD, Dana Farber Cancer Institute, Boston, MA

**Adult Clinical Malignant Hem**

**Jonathan B. Cohen**, MD, MS, Emory University, Atlanta, GA  
**Amy E. DeZern**, MD, Johns Hopkins University, Baltimore, MD  
**Loretta J. Nastoupil**, MD, The University of Texas MD Anderson Cancer Center, Houston, TX  
**Daniel A. Pollyea**, MD, University of Colorado, Denver, CO  
**Jennifer R. Brown**, MD, PhD, Dana-Farber Cancer Institute, Newton, MA  
**Aziz Nazha**, Cleveland Clinic, Cleveland, OH  
**Alison J. Moskowitz**, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Funding; BioInvent: Consultancy; Bristol-Myers Squibb: Research Funding; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees.

DizERN: Nothing to disclose.

NASTOUPIL: Gilead: Honoraria; Celgene: Honoraria, Research Funding; Genentech: Honoraria, Research Funding; Novartis: Honoraria; Spectrum: Honoraria; Janssen: Research Funding; TG Therapeutics: Research Funding; Karyopharm: Research Funding; Juno: Honoraria; Merck: Honoraria, Research Funding.

POLLEYA: AbbVie: Consultancy, Research Funding; Agios: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Argenx: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Celgene: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Karyopharm: Membership on an entity’s Board of Directors or advisory committees; Celyad: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Gilead: Consultancy.

BROWN: Aclaris / Astra-Zeneca: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Consultancy; Beigene: Membership on an entity’s Board of Directors or advisory committees; Boehringer: Consultancy; Celgene: Consultancy; Genentech: Consultancy; Gilead: Consultancy, Research Funding; Invectys: Membership on an entity’s Board of Directors or advisory committees; Janssen: Consultancy; Morphosys: Membership on an entity’s Board of Directors or advisory committees; Pharmacyclics: Consultancy; Roche/Genentech: Consultancy; Sun Pharmaceutical Industries: Research Funding; TG Therapeutics: Consultancy; Verastem: Consultancy, Research Funding; Loxo: Consultancy; Sunesis: Consultancy.

NAZHA: MIE: Consultancy.

MOSKOWITZ: Seattle Genetics: Consultancy, Honoraria, Research Funding; Bristol Myers-Squibb: Consultancy, Research Funding; Incyte: Research Funding; ADC Therapeutics: Research Funding; Takeda: Honoraria; Merck: Research Funding.

ELLIS: Alexion: Speakers Bureau.

JAIN: Astra Zeneca: Research Funding; Incyte: Research Funding; Seattle Genetics: Research Funding; Pfizer: Research Funding; Infinity: Research Funding; Verastem: Research Funding; Collectix: Research Funding; Pfizer: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pharmacyclics: Research Funding; Celgene: Research Funding; ADC Therapeutics: Research Funding; Verastem: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Servier: Research Funding; ADC Therapeutics: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; BMS: Research Funding; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; BMS: Research Funding; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novimmune: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity’s Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Adaptive Biotechnologies: Research Funding; Genentech: Research Funding; Adaptive Biotechnologies: Honoraria, Membership on an entity’s Board of Directors or advisory committees.

SCHNEIDENBERG: Janssen: Honoraria, Research Funding; Pfizer: Speakers Bureau; Novartis: Consultancy, Speakers Bureau.

REIN: Nothing to disclose.

HOFMANN: Nothing to disclose.

LOH: Nothing to disclose.

TASIAN: Nothing to disclose.

BAUMANN KREUZIGER: Nothing to disclose.

MARSHALL: Nothing to disclose.

Linnenberger: ABIM Hematology Board Exam Committee: Membership on an entity’s Board of Directors or advisory committees; American Society for Apheresis: Membership on an entity’s Board of Directors or advisory committees; American Society of Clinical Oncology: Membership on an entity’s Board of Directors or advisory committees.

CONNELL: The Michael H. Flanagan Foundation: Membership on an entity’s Board of Directors or advisory committees.

DONALD: Nothing to disclose.

McCRAE: Nothing to disclose.

GARCIA: Daiichi Sankyo: Research Funding; Incyte: Research Funding; Janssen: Consultancy, Research Funding; Pfizer: Consultancy; Portola: Research Funding; Shingos: Consultancy; Retham Technologies LLC: Consultancy; Genzyme Corporation: Consultancy; Bristol Meyers Squibb: Consultancy; Boehringer Ingelheim: Consultancy; Alexion: Consultancy.

SKEITH: Leo Pharma: Honoraria; CSL Behring: Research Funding.

Despotovic: Sanofi: Consultancy, Novartis: Research Funding; AmGen: Research Funding.

MANWANE: Nothing to disclose.

NeuNERT: Genzyme: Membership on an entity’s Board of Directors or advisory committees; Sanofi-Genzyme: Consultancy.
K2R Workshop

Moderator:

MARTHA P. MIMS, MD, PhD, Baylor College of Medicine, Houston, TX

The symposium targets NIH career development award recipients and ASH Scholars with the goal to provide attendees with information on how to move from an NIH K award to an NIH R award. The session takes place on Friday, November 30th, from 2:00 p.m. to 5:00 p.m. Three junior researchers will be invited to present in each of the three sessions; Basic, Translational, Education/Epi/Health Sciences. NIH officials and ASH past presidents will be invited to the program. They will not be invited to be faculty speakers or on the panel but to add additional advice and input to the attendees.

Disclosures:

MIMS: Nothing to disclose.

K2R Introduction

Friday 2:00 p.m. – 2:30 p.m. Padres Club House Petco Park

Chair:

MARTHA P. MIMS, MD, PhD, Baylor College of Medicine, Houston, TX

Disclosures:

MIMS: Nothing to disclose.

K2R Breakout 1: Basic Science

Friday 2:30 p.m. – 4:00 p.m. Padres Club House Petco Park

The K2R session targets NIH career development award recipients and ASH Scholars with the goal of providing attendees with information on how to move from a career-development award into an academic career or from an NIH K to R award. Two faculty members participate in each breakout (basic science, translational, education/epi/health services) where three pre-selected career-development awardees will present their research in 15-minute vignettes to be followed by a question and answer period. In total, there will be six faculty members and nine career development awardees.

Speakers:

Basic Science

PATRICIA C. LIAW, PhD, McMaster University, Hamilton, ON, Canada

Basic Science

DAVID GINSBURG, MD, Howard Hughes Medical Institute Life Science Institute, Ann Arbor, MI

Disclosures:

LIAW: Nothing to disclose.

GINSBURG: Portola pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Shire plc: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Syros Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees.

K2R Breakout 2: Translational Science

Friday 2:30 p.m. – 4:00 p.m. The Draft Petco Park

Speakers:
K2R Breakout 2: Translational Science
BARRY S. COLLER, MD, Lab of Blood & Vascular Biology, The Rockefeller University, New York, NY

Disclosures:
COLLER: Centocor: Patents & Royalties: Abciximab; Platelet Biogenesis: Consultancy; Rockefeller University: Patents & Royalties: RUC-4; Accumetrics: Patents & Royalties: VerifyNow Assays; CeleCor: Consultancy, Equity Ownership; Scholar Rock: Consultancy, Equity Ownership.

K2R Breakout 3: Education/ Epi/ Health Services

Friday 2:30 p.m. – 4:00 p.m.  Garden Dining Room
Petco Park

Speakers:

K2R Breakout 3: Education / Epi / Health Services
WILLIAM A. WOOD, MD, MPH, University of North Carolina, Chapel Hill, NC
MARY CUSHMAN, MD, MSC, Larner College of Medicine at the University of Vermont, Colchester, VT

Disclosures:
WOOD: Nothing to disclose.
CUSHMAN: Nothing to disclose.

K2R Panel Discussion

Friday 4:00 p.m. – 5:00 p.m. Padres Club House
Petco Park

Speakers:

K2R Panel Discussion
PATRICIA LIAW, PHD, McMaster University Div. of Hematology & Thromboembolism, Hamilton, ON, CAN
DAVID GINSBURG, MD, University of Michigan, Ann Arbor, MI
BARRY S. COLLER, MD, Lab of Blood & Vascular Biology, The Rockefeller University, New York, NY
WILLIAM A. WOOD, MD, MPH, University of North Carolina, Chapel Hill, NC
MARY CUSHMAN, MD, MSC, Larner College of Medicine at the University of Vermont, Colchester, VT

Disclosures:
LIAW: Nothing to disclose.
GINSBURG: Shire plc: Membership on an entity’s Board of Directors or advisory committees, Patents & Royalties; Portola pharmaceuticals: Membership on an entity’s Board of Directors or advisory committees; Syros Pharmaceuticals: Membership on an entity’s Board of Directors or advisory committees.
COLLER: Platelet Biogenesis: Consultancy; Accumetrics: Patents & Royalties: VerifyNow Assays; Rockefeller University: Patents & Royalties: RUC-4; CeleCor: Consultancy, Equity Ownership; Scholar Rock: Consultancy, Equity Ownership; Centocor: Patents & Royalties: Abciximab.
WOOD: Nothing to disclose.
CUSHMAN: Nothing to disclose.
SATURDAY

Career Development Lunch Sessions

Moderator:
ANN S. LA CASCE, MD, MSC, Dana-Farber Cancer Inst., Boston, MA

These sessions will provide an intimate venue for trainees to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research, PhD careers, careers in Industry settings, and careers in private and clinical practice. There will be two rooms reserved for these sessions, with two tables per room for each career area and one faculty member at each table leading the discussion.

A boxed lunch will be provided. Space is available on a first-come, first-served basis. As seating is limited, attendees are strongly encouraged to arrive early. No additional participants will be allowed in the rooms once these sessions are filled.

Disclosures:
LA CASCE: Nothing to disclose.

Career-Development Lunch Session Ballroom AB

Saturday 11:15 a.m. – 12:15 p.m. Sapphire Ballroom AB
Hilton San Diego Bayfront

Chair:
ANN S. LA CASCE, MD, MSC, Dana-Farber Cancer Inst., Boston, MA

This session will provide an intimate venue for trainees to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research, PhD careers, careers in industry settings, and careers in private and clinical practice.

There will be two rooms reserved for this session, with two tables per room for each career area and one faculty member at each table leading the discussion. A boxed lunch will be provided.

Speakers:

Adult Clinical Malignant Hematology/BMT 1
NAVNEET S. MAJHAIL, MD, MS, Cleveland Clinic, Cleveland, OH

Adult Clinical Malignant Hematology/BMT 4
MICHAEL SCORDO, MD, Memorial Sloan-Kettering Cancer Center/New York, New York, NY

Pediatric Clinical Malignant Hematology/BMT 2
CHRISTOPHER C. DVORAK, MD, University of California – San Francisco, San Francisco, CA

Pediatric Clinical Malignant Hematology/BMT 3
SARAH K. TASIAN, MD, Children's Hospital of Philadelphia, Philadelphia, PA

Adult Clinical Non-Malignant Hematology 1
COLLEEN MORTON, MD, Vanderbilt University Medical Center, Nashville, TN

Adult Clinical Non-Malignant Hematology 4
ANJLEE MAHAJAN, MD, UC Davis, Sacramento, CA

Pediatric Clinical Non-Malignant Hematology 1
DEEPA MANWANI, MD, Albert Einstein College of Medicine, Bronx

Pediatric Clinical Non-Malignant Hematology 2
ROBERT LIEM, MD, Lurie Children's Hospital, Chicago, IL
Laboratory and Translational Hematology
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN

Allogeneic Cell Transplantation and Cell Therapy
Katharine C. Hsu, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY

Industry Careers 1
Michael Pourdehnad, MD, Celgene Corporation, San Francisco, CA

Industry Careers 4
Melissa Jeanne Eisen, MD, Amgen Inc., Thousand Oaks, CA

Government Careers (FDA and NIH) 3
Laurel A Menapace, MD, U.S. Food and Drug Administration, Silver Spring, MD

Government Careers (NIH) 4
Ericka Boone, Ph.D., National Institutes of Health, Bethesda, MD

PhD Careers 2
Lawrence H. Boise, PhD, Emory University, Atlanta, GA

PhD Careers 3
Ishac Nazy, PhD, McMaster University, Hamilton, ON, Canada

Clinical Careers in Hematology (Private Practice) 1
Michael D. Tarantino, MD, The Bleeding & Clotting Disorders Institute, Peoria, IL

Clinical Careers in Hematology (Private Practice) 4
Chancellor E. Donald, MD, Tulane University School of Medicine, New Orleans, LA

Medical Educators in Hematology 1
Marc J Kahn, MD, MBA, Tulane University, New Orleans, LA

Medical Educators in Hematology 4
Jennifer Green, MD, Vanderbilt University Medical Center, Nashville, TN

Transfusion Medicine 3
Justin D. Kreuter, MD, Mayo Clinic, Rochester, MN

Transfusion Medicine 4
Richard M Kalfman, MD, Brigham and Women’s Hospital, Boston, MA

Disclosures:
Lacasse: Nothing to disclose.
Majhail: Incyte: Honoraria; Atara: Honoraria; Anthem, Inc.: Consultancy.
Scordo: Nothing to disclose.
Dvorak: Jazz Pharmaceuticals: Consultancy; Chimerix, Inc.: Membership on an entity’s Board of Directors or advisory committees.
Tasian: Aleita Biopharmaceuticals: Membership on an entity’s Board of Directors or advisory committees; Gilead Sciences: Research Funding; Incyte Corporation: Research Funding.
Morton: Nothing to disclose.
Mahajan: Nothing to disclose.
Manwani: Nothing to disclose.
Liem: Nothing to disclose.
Lin: Nothing to disclose.
Hsu: Nothing to disclose.
Pourdehnad: Nothing to disclose.
Eisen: Amgen Inc.: Employment, Equity Ownership.
Menapace: Nothing to disclose.
Boone: Nothing to disclose.
Boise: Abbvie: Consultancy; AstraZeneca: Honoraria.
Nazy: Nothing to disclose.
TARANTINO: Health Resources and Services Administration: Research Funding; Centers for Disease Control and Prevention: Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees; Genentech: Membership on an entity's Board of Directors or advisory committees; Shire: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Other: Reviews grants; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Grifols: Research Funding, Speakers Bureau.

DONALD: Nothing to disclose.

KAHN: Association of American Medical Colleges: Membership on an entity's Board of Directors or advisory committees; National Residency Match Program: Membership on an entity's Board of Directors or advisory committees; National Residency Matching Program: Membership on an entity's Board of Directors or advisory committees; Association of American Medical Colleges: Membership on an entity's Board of Directors or advisory committees; National Residency Match Program: Membership on an entity's Board of Directors or advisory committees; National Residency Matching Program: Membership on an entity's Board of Directors or advisory committees.

GREEN: Nothing to disclose.

KREUTER: Nothing to disclose.

KAUFMAN: Nothing to disclose.

Career Development Lunch Session Ballroom EF

Saturday  11:15 a.m. – 12:15 p.m. Sapphire Ballroom EF
Hilton San Diego Bayfront

Chair:
ANN S. LACASCE, MD, MSC, Dana-Farber Cancer Inst., Boston, MA

Speakers:

Adult Clinical Malignant Hematology/BMT 2
TANYA WILDES, MD, Washington University, Saint Louis, MO

Adult Clinical Malignant Hematology/BMT 3
SAAR I. GILL, MD, PhD, University of Pennsylvania, Philadelphia, PA

Pediatric Clinical Malignant Hematology/BMT 1
PETER D. COLE, MD, Montefiore Medical Center, Bronx, NY

Pediatric Clinical Malignant Hematology/BMT 4
E. ANDERS KOLB, MD, Nemours Alfred I. duPont Hospital for Children, Wilmington, DE

Adult Clinical Non-Malignant Hematology 2
JEFFREY I. ZWICKER, MD, Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA

Adult Clinical Non-Malignant Hematology 3
JODI V MONES, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Pediatric Clinical Non-Malignant Hematology 3
CINDY NEUNERT, MD, Columbia University, New York, NY

Pediatric Clinical Non-Malignant Hematology 4
AMANDA M. BRANDOW, DO, MS, Medical College of Wisconsin, Milwaukee, WI

Laboratory and Translational Hematology 1
WOLFRAM RIIP, MD, Johannes Gutenberg University Medical Center, Mainz, Germany

Laboratory and Translational Hematology 3
ANNE WINKLER, MD, Instrumentation Laboratory, Bedford, MA

Industry Careers 2
ARATI V RAO, MD, Kite - a Gilead company, Foster City, CA

Industry Careers 3
RAMON TRI, MD, Lilly Corporate Center, Indianapolis, IN
Disclosures:

LA CASCE: Nothing to disclose.

WILDES: Jansen: Research Funding.

GILL: Carisma Therapeutics: Equity Ownership; Estella: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Research Funding.

COLE: Nothing to disclose.

KOLB: Servier: Membership on an entity's Board of Directors or advisory committees; Roche-Genentech: Membership on an entity's Board of Directors or advisory committees.

ZWICKER: Daiichi: Honoraria; Quagen: Research Funding; Patexel: Consultancy; Incyte: Research Funding.

MONES: Nothing to disclose.

NEUNERT: Sanofi-Genzyme: Consultancy; Genzyme: Membership on an entity's Board of Directors or advisory committees.

BRANDOW: Nothing to disclose.

RUI: Iconic Therapeutics: Membership on an entity's Board of Directors or advisory committees; MeruVaxImmune: Membership on an entity's Board of Directors or advisory committees.

WINKLER: Instrumentation Laboratory: Employment.


DI MICHELE: Nothing to disclose.

BISHOP: Nothing to disclose.

TYNER: AstraZeneca: Research Funding; Genentech: Research Funding; Gilead: Research Funding; Incyte: Research Funding; Jansen: Research Funding; Syros: Research Funding; Takeda: Research Funding; Seattle Genetics: Research Funding; Leap Oncology: Equity Ownership; Apteose: Research Funding; Agios: Research Funding.

AIFANTIS: Nothing to disclose.

FISHKIN: Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria; Novartis: Equity Ownership.

TAM: Nothing to disclose.

ELLIS: Alexion: Speakers Bureau.

MARSHALL: Nothing to disclose.

DZIK: Nothing to disclose.
Junior Faculty Career-Development Session

Saturday 2:00 p.m. – 3:30 p.m.  Room 25B

Education Session. This session is only offered once.

Chair:
REBECCA L. OLIN, MD, University of California, San Francisco, San Francisco, CA

Speakers:
NATHAN T. CONNELL, MD, MPH, Brigham and Women's Hospital, Boston, MA

The Difference Between a Coach and Mentor
ALISON W. LOREN, MD, MS, Perelman Center For Advanced Medicine, Philadelphia, PA

The Warning Signs of a Problematic Mentoring Relationship and How to Fix It
CHARALAMBOS ANDREADIS, MD, UCSF, San Francisco, CA

What Works: Transitioning From Being a Trainee to Becoming a Coach

During this session, junior faculty will cover career-development topics, including mentorship. Speakers will discuss how to receive, provide, and optimize mentorship.

Disclosures:
OLIN: Synapse: Honoraria; Daiichi Sankyo: Research Funding; Genentech: Research Funding; Astellas: Research Funding.
CONNELL: The Michael H. Flanagan Foundation: Membership on an entity’s Board of Directors or advisory committees.
LOREN: No relevant conflicts of interest to declare.
ANDREADIS: Genentech: Consultancy, Employment; Celgene: Consultancy; Gilead: Consultancy; Pharmacyclics: Consultancy; Kite: Consultancy; Seattle Genetics: Consultancy; Bayer: Consultancy; Astellas: Consultancy; Novartis: Consultancy, Research Funding; Juno: Research Funding.
Hematology Course Directors’ Workshop

Special-Interest Session

Sunday 7:00 a.m. – 9:00 a.m.  Cobalt 500, Hilton San Diego Bayfront

Chair:
RAKESH P. MEHTA, MD, Indiana University School of Medicine, Indianapolis, IN

Speakers:
TIMOTHY JAMES J. LITTLEWOOD, MD, University of Oxford, Oxford, United Kingdom

Teaching Hematology: Art, Science, and Humanity

This workshop is intended to provide course directors and others involved in teaching hematology to medical students with opportunities to learn about issues facing them. It is designed to facilitate discussion and the sharing of best practices in critical training areas.

Disclosures:
MEHTA: Nothing to disclose.
LITTLEWOOD: Nothing to disclose.
Trainee Didactic Sessions

Moderator:
MORIE A. GERTZ, MD, Mayo Clinic, Rochester, MN

During lunch on Sunday and Monday, ASH will offer didactic sessions designed to provide trainees with an overview of timely and relevant career-oriented issues. Space is available on a first-come, first-served basis. As seating is limited, attendees are strongly encouraged to arrive early. No additional participants will be allowed in the rooms once these sessions are filled.

Disclosures:
GERTZ: Nothing to disclose.

Trainee Didactic Session 1: Mentoring and Being Mentored

Sunday 11:15 a.m. – 12:15 p.m. Room 31B
San Diego Convention Center

Chair:
MORIE A. GERTZ, MD, Mayo Clinic, Rochester, MN

These didactic sessions are designed to provide trainees with an overview of timely and relevant career-oriented issues.

Speakers:

Mentoring and Being Mentored
RIMA JUBRAN, MD, MPH, Children's Hospital Los Angeles, Los Angeles, CA

Mentoring and Being Mentored
SHERIF M. BADAWY, MD, MS, Ann & Robert H. Lurie Children’s Hospital of Chicago, Feinberg School of Medicine Northwestern University, Chicago, IL

Disclosures:
GERTZ: Nothing to disclose.
JUBRAN: Nothing to disclose.
BADAWY: Nothing to disclose.

Trainee Didactic Session 2: Basic Statistics for Hematologists

Sunday 11:15 a.m. – 12:15 p.m. Room 33B
San Diego Convention Center

Speakers:

Basic Statistics for Hematologists
ANTJE HOERING, PhD, Cancer Research and Biostatistics, Seattle, WA

Disclosures:
HOERING: Nothing to disclose.
MONDAY

Trainee Didactic Sessions

Moderator:

MORIE A. GERTZ, MD, Mayo Clinic, Rochester, MN

During lunch on Sunday and Monday, ASH will offer didactic sessions designed to provide trainees with an overview of timely and relevant career-oriented issues. Space is available on a first-come, first-served basis. As seating is limited, attendees are strongly encouraged to arrive early. No additional participants will be allowed in the rooms once these sessions are filled.

Disclosures:

GERTZ: Nothing to disclose.

Trainee Didactic Session 3: How to Set Up a Clinical Research Program

Monday 12:15 p.m. – 1:15 p.m.  Room 31B
San Diego Convention Center

Speakers:

How to Set Up a Clinical Research Program
AYALEW TEFFERI, MD, Mayo Clinic, Rochester, MN

Disclosures:

TEFFERI: Nothing to disclose.

Trainee Didactic Session 4: Bridging the Gap: How to Find Clinicians (PhD Topic)

Monday 12:15 p.m. – 1:15 p.m.  Room 33B
San Diego Convention Center

Speakers:

Bridging the Gap: How to Find Clinicians (PhD Topic)
ANUPRIYA AGARWAL, PhD, Oregon Health & Science University, Portland, OR

Disclosures:

AGARWAL: Nothing to disclose.